This study is testing a potential new treatment for EPP or XLP that increases melanin in the skin, which protects you from sunlight.
- Prof David Coman
Clinical Trial Coordinator
- Venita Bali
A Phase 3, Multicenter, Open-Label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)
About this research project
Erythropoietic Protoporphyria (referred to as“EPP”) or X-Linked Protoporphyria (referred to as “XLP”) are characterized by the accumulation of a molecule named protoporphyrin in the body, which leads to pain when the skin is exposed to sunlight. The purpose of this trial is to investigate whether an experimental drug called MT-7117 (Dersimelagon) is effective and well tolerated in reducing the severity of symptoms of EPP or XLP.